Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.130
-0.190 (-5.72%)
At close: Oct 14, 2026, 4:00 PM EDT
3.129
-0.001 (-0.02%)
After-hours: Oct 14, 2026, 7:57 PM EDT
Prime Medicine Revenue
Prime Medicine had revenue of $1.15M in the quarter ending June 30, 2026, with 3.50% growth. This brings the company's revenue in the last twelve months to $4.07M, down -17.90% year-over-year. In the year 2025, Prime Medicine had annual revenue of $4.63M with 55.28% growth. That makes Prime Medicine the 40,579th largest company in the world by revenue and 5,425th in the United States.
Revenue (ttm)
$4.07M
Revenue Growth
-17.90%
P/S Ratio
136.72
Revenue / Employee
$27,897
Employees
146
Market Cap
556.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.63M | 1.65M | 55.28% |
| Dec 31, 2024 | 2.98M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| MiMedx Group | 355.17M |
| Zevra Therapeutics | 136.07M |
| Wave Life Sciences | 65.37M |
| OmniAb | 38.46M |
| Crescent Biopharma | 11.88M |
| Avalo Therapeutics | 59.00K |
PRME News
- 9 days ago - Prime Medicine doses first patient in PM577a trial - TheFly
- 9 days ago - Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease - GlobeNewsWire
- 10 days ago - Prime Medicine Slides: Corporate presentation - Filings
- 20 days ago - Prime Medicine announces FDA clearance of IND application for PM647 - TheFly
- 20 days ago - Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 4 weeks ago - Prime Medicine Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Prime Medicine Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire